Segment Information - Schedule of Segment Reporting Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Segment Reporting Information [Line Items]
Revenues	$ 27,172	$ 24,931
Cost of revenues	979	1,125
Gross profit	26,193	23,806
Operating expenses excluding cost of revenues:
Selling and marketing	12,542	12,768
Research and development	2,182	2,635
General and administrative	3,398	1,739
Total operating expenses excluding cost of revenues	18,122	17,142
Income from operations	8,071	6,664
Supplemental disclosure of stock-based compensation expense:
Stock-based compensation	11
Total assets	122,010		$ 116,539
Purchase of property and equipment	231	1,742
General and administrative
Supplemental disclosure of stock-based compensation expense:
Stock-based compensation	11
Gyre Pharmaceuticals
Segment Reporting Information [Line Items]
Revenues	27,172	24,931
Cost of revenues	979	1,125
Gross profit	26,193	23,806
Operating expenses excluding cost of revenues:
Selling and marketing	12,542	12,768
Research and development	2,009	2,635
General and administrative	2,257	1,722
Total operating expenses excluding cost of revenues	16,808	17,125
Income from operations	9,385	6,681
Supplemental disclosure of stock-based compensation expense:
Total assets	109,347		101,761
Purchase of property and equipment	217	1,742
Gyre
Operating expenses excluding cost of revenues:
Research and development	173
General and administrative	1,141
Total operating expenses excluding cost of revenues	1,314
Income from operations	(1,314)
Supplemental disclosure of stock-based compensation expense:
Stock-based compensation	11
Total assets	11,750		13,865
Purchase of property and equipment	14
Gyre | General and administrative
Supplemental disclosure of stock-based compensation expense:
Stock-based compensation	11
Other
Operating expenses excluding cost of revenues:
General and administrative		17
Total operating expenses excluding cost of revenues		17
Income from operations		$ (17)
Supplemental disclosure of stock-based compensation expense:
Total assets	$ 913		$ 913